Patents & Power in the India–EU Free Trade Agreement

EuroScope @ Global Eye Intelligence presents a timely and high-impact policy brief on one of the most sensitive fault lines in the India–EU Free Trade Agreement: intellectual property rights (IPR). Patents & Power dissects the strategic tug-of-war between European demands for stronger patent protection and India’s long-standing commitment to affordable medicines, public health safeguards, and TRIPS-compliant flexibility.

This report explains why issues such as data exclusivity, patent term extensions, and enforcement mechanisms remain politically explosive despite formal closure of the IPR chapter. It unpacks how India’s domestic legal architecture—especially Section 3(d) of the Patents Act—has become a global benchmark against patent “evergreening,” while also detailing the EU’s push for TRIPS-plus standards that could reshape pharmaceutical innovation and market access worldwide.

Beyond legal nuance, this brief highlights the global consequences of the India–EU IPR debate—from access to generic medicines in developing countries to the future of innovation incentives and trade precedent-setting. It also outlines potential compromise pathways inspired by recent trade agreements.

If you track trade policy, pharmaceuticals, global health, or India–EU relations, this is essential reading.

Follow EuroScope @ Global Eye Intelligence to stay ahead of negotiations that will shape innovation power and public health globally. Download this policy brief now.

Keywords: India EU IPR dispute, patents in India EU FTA, pharmaceutical trade policy, data exclusivity debate, TRIPS compliance India, EuroScope policy brief, intellectual property geopolitics, Global Eye Intelligence Europe.